Carmell Therapeutics to acquire Axolotl Biologix for $140m.

Carmell Therapeutics, a regenerative medicine company, agreed to acquire Axolotl Biologix, a profitable regenerative medicine company, for $140m. "I look forward to working with Josh and the Axolotl team to accelerate our goal of building Carmell into an Industry-leading regenerative medicine company through a combination of in-house product development, bolt-on acquisitions and business development aimed at aesthetics/soft tissue and orthopedic indications," Mr. Rajiv Shukla, Carmell Executive Chairman.